Group B Streptococcus Vaccine: full value vaccine assessment
Overview
Group B streptococcus (GBS) is an important cause of disease
burden in every region worldwide, contributing to neonatal/
infant infection, deaths, disability, stillbirths and maternal infection. The World Health Organization (WHO) identified the development of GBS vaccines suitable for maternal immunization in
pregnancy and use in low- and middle-income countries (LMICs)
as a priority in 2015.
The purpose of this report, WHO Full value
of vaccines assessment of Group B streptococcus vaccines is to
describe the global public health rationale for developing vaccines against disease caused by GBS for maternal immunization, to inform decision making across the continuum of vaccine
development and uptake with a line of sight to sustainable public health impact.
